Stéphanie Lheureux

Research interests

Publications

• First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

  Journal of Clinical Oncology · 2024 · 10.1200/jco-24-01326

• First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

  Journal of Clinical Oncology · 2024 · 10.1200/jco-24-01326

• Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.00954

• MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer

  Supportive Care in Cancer · 2022 · 10.1007/s00520-022-06889-8

• Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

  Journal for ImmunoTherapy of Cancer · 2022 · 10.1136/jitc-2021-004233

• Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment

  Seminars in Cancer Biology · 2022 · https://doi.org/10.1016/j.semcancer.2022.03.027

• ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)

  International Journal of Gynecological Cancer · 2021 · 10.1136/ijgc-2021-002973

• Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

  Nature Communications · 2021 · 10.1038/s41467-021-25432-7

• Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer

  Journal of the National Comprehensive Cancer Network · 2021 · 10.6004/jnccn.2020.7803

• Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

  Nature Cancer · 2020 · https://doi.org/10.1038/s43018-020-0096-5

• PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.01924

• An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

  Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2020-000883

• FIGO 2018 stage IB2 (2–4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study

  International Journal of Gynecological Cancer · 2019 · 10.1136/ijgc-2019-000398

• Epithelial ovarian cancer: Evolution of management in the era of precision medicine

  CA A Cancer Journal for Clinicians · 2019 · https://doi.org/10.3322/caac.21559

• Epithelial ovarian cancer

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32552-2

• A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-18-1244

• Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors

  Genome Medicine · 2018 · 10.1186/s13073-018-0590-x

• Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.70.3439

• Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

  European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 10.1007/s00259-017-3695-3

• Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy

  Molecular Oncology · 2016 · 10.1016/j.molonc.2016.03.005

• Treatment strategies for endometrial cancer: current practice and perspective

  Current Opinion in Obstetrics & Gynecology · 2016 · https://doi.org/10.1097/gco.0000000000000338

• A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

  Gynecologic Oncology · 2015 · 10.1016/j.ygyno.2015.04.009

• F18-Choline, a Novel PET Tracer for Parathyroid Adenoma?

  The Journal of Clinical Endocrinology & Metabolism · 2013 · 10.1210/jc.2013-2084

• Nanocarriers for the targeted treatment of ovarian cancers

  Biomaterials · 2012 · 10.1016/j.biomaterials.2012.10.055

Current projects

No projects listed.